Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Artiva Biotherapeutics Inc (ARTV)

Artiva Biotherapeutics Inc (ARTV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 91,798
  • Shares Outstanding, K 24,545
  • Annual Sales, $ 250 K
  • Annual Income, $ -65,370 K
  • EBIT $ -86 M
  • EBITDA $ -84 M
  • 60-Month Beta 2.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.87
  • Number of Estimates 3
  • High Estimate -0.81
  • Low Estimate -0.91
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.62 +7.46%
on 02/09/26
5.16 -24.61%
on 01/12/26
-0.96 (-19.88%)
since 01/09/26
3-Month
2.96 +31.42%
on 12/09/25
7.25 -46.34%
on 12/15/25
+0.23 (+6.28%)
since 11/10/25
52-Week
1.47 +164.63%
on 06/27/25
7.36 -47.15%
on 10/17/25
-0.15 (-3.71%)
since 02/10/25

Most Recent Stories

More News
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued...

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible...

ARTV : 3.89 (+4.01%)
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were...

ARTV : 3.89 (+4.01%)
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®,...

ARTV : 3.89 (+4.01%)
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET Initial safety data for 32 patients with autoimmune disease treated with AlloNK + monoclonal antibody (mAb) therapy,...

ARTV : 3.89 (+4.01%)
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) --   Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies...

ARTV : 3.89 (+4.01%)
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies...

ARTV : 3.89 (+4.01%)
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

First patient treated in company-sponsored global basket trial exploring AlloNK ® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic...

ARTV : 3.89 (+4.01%)
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

ARTV : 3.89 (+4.01%)
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

ARTV : 3.89 (+4.01%)
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

ARTV : 3.89 (+4.01%)

Business Summary

Artiva Biotherapeutics Inc. is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company's lead program includes AlloNK(R). Artiva Biotherapeutics Inc. is based in SAN DIEGO....

See More

Key Turning Points

3rd Resistance Point 4.35
2nd Resistance Point 4.22
1st Resistance Point 4.06
Last Price 3.89
1st Support Level 3.77
2nd Support Level 3.64
3rd Support Level 3.48

See More

52-Week High 7.36
Fibonacci 61.8% 5.11
Fibonacci 50% 4.41
Last Price 3.89
Fibonacci 38.2% 3.72
52-Week Low 1.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar